Tactile Systems Technology (TCMD) Panoramica del titolo
Tactile Systems Technology, Inc. è un'azienda di tecnologie mediche che sviluppa e fornisce dispositivi medici per il trattamento di malattie croniche poco conosciute negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 4/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
TCMD Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Tactile Systems Technology, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$28.17 |
| Massimo di 52 settimane | US$37.77 |
| Minimo di 52 settimane | US$9.60 |
| Beta | 0.79 |
| Variazione di 1 mese | -8.09% |
| Variazione a 3 mesi | 23.07% |
| Variazione di 1 anno | 191.92% |
| Variazione a 3 anni | 34.85% |
| Variazione a 5 anni | -35.49% |
| Variazione dall'IPO | 154.24% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 23
TCMD: Margin Expansion And New Therapies Will Support Future Upside
Analysts have lifted their fair value estimate for Tactile Systems Technology to $42.00 from $32.00, citing expectations for stronger profit margins and a slightly higher future P/E multiple, as reflected in recent Street research updates. What’s in the News for Tactile Systems Technology Tactile Systems Technology entered an exclusive distribution agreement with ElastiMed to provide the MyoSleeve non pneumatic lower leg compression device to U.S. Department of Veterans Affairs and Department of Defense patients, with a US$3 million upfront payment, minimum purchase commitments, and planned use of the company’s existing sales and support infrastructure.Seeking Alpha • Jul 14
Tactile Systems: Clean Balance Sheet, But A Possible Value Trap
Summary Tactile Systems Technology is rated Hold, with a 12-month price target of $31, reflecting fair value near 20x P/E. TCMD's strong balance sheet—$83.4M cash, zero debt—and raised guidance are already priced in, limiting upside. Peer history shows cheap, mature MedTech stocks with reimbursement risk tend to underperform, suggesting limited near-term appreciation for TCMD. The key catalyst is the CMS prior-authorization rollout; Q2 results will determine if TCMD can break the value trap pattern. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 09
TCMD: Index Inclusion And New Respiratory Platform Will Drive Future Upside
Analysts have increased their fair value estimate for Tactile Systems Technology from $16.00 to $36.00, citing updated assumptions around revenue growth, profit margins, and future P/E multiples, which are reflected in recent price target revisions such as the increase highlighted by BTIG. What’s in the News for Tactile Systems Technology Tactile Systems Technology announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system, with updates focused on patient comfort, ease of use, and connected care capabilities across pediatric and geriatric respiratory patients.Recent updates
Aggiornamento narrativa • Jul 23
TCMD: Margin Expansion And New Therapies Will Support Future Upside
Analysts have lifted their fair value estimate for Tactile Systems Technology to $42.00 from $32.00, citing expectations for stronger profit margins and a slightly higher future P/E multiple, as reflected in recent Street research updates. What’s in the News for Tactile Systems Technology Tactile Systems Technology entered an exclusive distribution agreement with ElastiMed to provide the MyoSleeve non pneumatic lower leg compression device to U.S. Department of Veterans Affairs and Department of Defense patients, with a US$3 million upfront payment, minimum purchase commitments, and planned use of the company’s existing sales and support infrastructure.Seeking Alpha • Jul 14
Tactile Systems: Clean Balance Sheet, But A Possible Value Trap
Summary Tactile Systems Technology is rated Hold, with a 12-month price target of $31, reflecting fair value near 20x P/E. TCMD's strong balance sheet—$83.4M cash, zero debt—and raised guidance are already priced in, limiting upside. Peer history shows cheap, mature MedTech stocks with reimbursement risk tend to underperform, suggesting limited near-term appreciation for TCMD. The key catalyst is the CMS prior-authorization rollout; Q2 results will determine if TCMD can break the value trap pattern. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 09
TCMD: Index Inclusion And New Respiratory Platform Will Drive Future Upside
Analysts have increased their fair value estimate for Tactile Systems Technology from $16.00 to $36.00, citing updated assumptions around revenue growth, profit margins, and future P/E multiples, which are reflected in recent price target revisions such as the increase highlighted by BTIG. What’s in the News for Tactile Systems Technology Tactile Systems Technology announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system, with updates focused on patient comfort, ease of use, and connected care capabilities across pediatric and geriatric respiratory patients.
Aggiornamento narrativa • Jun 25
TCMD: Connected Care Rollout And Buybacks Will Support Future Upside
Analysts have raised their price target on Tactile Systems Technology by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which together support a slightly higher valuation framework. What's in the News Tactile Systems Technology announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system, aimed at chronic neuromuscular and respiratory conditions across pediatric and geriatric patients, with updates focused on comfort, ease of use, and connected care features.Aggiornamento narrativa • Jun 07
TCMD: Connected Care Launch And Governance Changes Will Support Continued Upside
Analysts have nudged their price target on Tactile Systems Technology to $39.50 from $38, reflecting updated views on fair value, discount rate, revenue growth, profit margin assumptions, and expected future P/E, as highlighted in recent Street research. What's in the News Tactile Systems Technology announced the full commercial launch of its next generation AffloVest high frequency chest wall oscillation therapy system, designed to support long term adherence for chronic neuromuscular and respiratory conditions across pediatric and geriatric patients.Aggiornamento narrativa • Apr 23
TCMD: Lymphedema Execution And Multi Year Guidance Will Support Continued Upside
Analysts have lifted the consolidated price target for Tactile Systems Technology to around $38, supported by higher projections for revenue growth, improved profit margins, and a lower assumed future P/E multiple following recent Q4 upside and updated multi year guidance. Analyst Commentary Recent Street research on Tactile Systems Technology highlights a range of views on execution, growth prospects, and valuation following the Q4 results and updated multi year guidance.Articolo di analisi • Apr 18
Should You Think About Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD) Now?
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), might not be a large cap stock, but it received a lot of attention...Aggiornamento narrativa • Apr 08
TCMD: Lymphedema Momentum And Q4 Execution Will Drive Multi Year Upside
The updated analyst price target for Tactile Systems Technology has been set at $38. This reflects analysts' reactions to recent Q4 outperformance, higher long-term estimates, and ongoing attention to productivity, patient referrals, and the lymphedema business.Aggiornamento narrativa • Mar 25
TCMD: Lymphedema Momentum And Q4 Execution Will Support Multi Year Upside
Analysts have lifted the consolidated price target for Tactile Systems Technology to $38, reflecting a series of Street target increases into the $32 to $42 range, supported by recent Q4 outperformance, updated multi year guidance, and progress in productivity and cost controls. Analyst Commentary Street commentary around Tactile Systems Technology is mixed, with several bullish analysts lifting targets on the back of Q4 execution and longer term guidance, while more cautious voices question how much upside remains after the post earnings re rating.Aggiornamento narrativa • Mar 09
TCMD: Lymphedema Momentum And Q4 Execution Will Support Ongoing Upside Potential
Analysts have nudged their average price target for Tactile Systems Technology to $38. This reflects stronger recent Q4 execution, raised long term estimates and ongoing improvements in productivity, patient referrals and cost controls.Aggiornamento narrativa • Feb 23
TCMD: Lymphedema Momentum And Q4 Execution Will Support Measured Turnaround Expectations
The analyst fair value estimate for Tactile Systems Technology has been raised from $29.75 to $38.00, reflecting higher Street price targets in the $32 to $42 range as analysts cite recent Q4 upside, improved productivity and cost controls, and ongoing strength in the lymphedema business. Analyst Commentary Street research on Tactile Systems Technology is generally constructive, with higher fair value assumptions linked to recent Q4 performance, execution on productivity and cost controls, and expectations around the lymphedema business.Aggiornamento narrativa • Feb 08
TCMD: Index Inclusion And Stable Outlook Will Shape Measured Turnaround Expectations
Analysts have maintained their fair value estimate for Tactile Systems Technology at $29.75 per share. They cited only very small adjustments to assumptions regarding the discount rate, revenue growth, profit margins, and future P/E multiples, rather than any change in the core outlook.Aggiornamento narrativa • Jan 25
TCMD: Turnaround Momentum And Buyback Will Test Q3 Outperformance Sustainability
Analysts have raised their price targets on Tactile Systems Technology to a roughly mid to high $20s to low $30s range, citing stronger than expected Q3 results, improved productivity, sales force expansion, new products, and better reimbursement trends that together support a higher fair value assessment. Analyst Commentary Recent research points to a more constructive view on Tactile Systems Technology following its Q3 outperformance, with several firms raising price targets and upgrading ratings based on execution and perceived upside to fair value.Aggiornamento narrativa • Jan 10
TCMD: Q3 Turnaround Momentum And Buyback Will Face Execution Risk
Analysts have raised their price target on Tactile Systems Technology to about $29.75 from $24, citing stronger recent earnings performance, expectations for operational improvements, and support for a higher future P/E multiple. Analyst Commentary Recent research updates on Tactile Systems Technology highlight a clear shift toward a more constructive stance, with multiple firms lifting price targets after Q3 results and pointing to both execution progress and valuation support.Articolo di analisi • Dec 18
Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 28%
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have continued their recent momentum with a 28% gain in the...Aggiornamento narrativa • Dec 17
TCMD: Q3 Outperformance And Buyback Will Mask Limited Upside Ahead
Analysts have raised their price target on Tactile Systems Technology by about $8.50 to roughly $32 per share, citing significant Q3 outperformance, improving productivity and reimbursement trends, and expectations for a return to double digit growth by 2026. Analyst Commentary Recent research updates reflect a notably more constructive stance on Tactile Systems Technology, with bullish analysts pointing to operational momentum, clearer reimbursement visibility, and a sizable underpenetrated patient pool as key drivers of potential upside in the shares.Aggiornamento narrativa • Dec 03
TCMD: Q3 Outperformance And Buyback Plan Will Shape Turnaround Outlook
Analysts have raised their price expectations for Tactile Systems Technology toward the low to mid $30 range, citing a massive Q3 outperformance, consistent estimate beats, and growing confidence in a 2026 growth reacceleration and higher sustainable earnings power. Analyst Commentary Recent Street research reflects a broadly constructive stance on Tactile Systems Technology following its strong Q3 performance and improving fundamentals.Aggiornamento narrativa • Nov 19
TCMD: Sustained Product Execution And Buyback Plan Set To Shape Outlook
Analysts have raised their price target on Tactile Systems Technology significantly, from approximately $16.83 to $24.00. They cite strong quarterly outperformance and growing confidence in the company’s turnaround and future growth prospects.Articolo di analisi • Nov 06
Results: Tactile Systems Technology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) investors will be delighted, with the company turning in some strong...Aggiornamento narrativa • Nov 03
TCMD: Market Leadership And Coverage Momentum Will Drive Expansion Into Underserved Patients
Narrative Update on Tactile Systems Technology Analysts have reaffirmed their price target for Tactile Systems Technology at $16.83 per share. They cite the company's leadership in key market segments and anticipated growth acceleration as a result of recent strategic improvements.Aggiornamento narrativa • Oct 20
At-home Healthcare And Workflow Automation Will Expand Patient Reach
Analysts have maintained their price target for Tactile Systems Technology at $23.50. They cite the company's leading positions in key device markets and an improved outlook following recent strategic adjustments.Aggiornamento narrativa • Oct 05
At-home Healthcare And Workflow Automation Will Expand Patient Reach
Analysts have raised their fair value estimate for Tactile Systems Technology from $13.50 to $16.83 per share. The change is attributed to optimism about the company's strengthened market leadership and the potential for renewed growth following recent strategic improvements.Articolo di analisi • Oct 04
When Should You Buy Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it saw a significant share...Articolo di analisi • Aug 29
Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Shares Leap 28% Yet They're Still Not Telling The Full Story
Despite an already strong run, Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have been powering on, with a...Articolo di analisi • May 12
Tactile Systems Technology's (NASDAQ:TCMD) Soft Earnings Don't Show The Whole Picture
The most recent earnings report from Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) was disappointing for...Articolo di analisi • May 08
Slammed 28% Tactile Systems Technology, Inc. (NASDAQ:TCMD) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares are down a considerable...Articolo di analisi • May 07
Why Tactile Systems Technology, Inc. (NASDAQ:TCMD) Could Be Worth Watching
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it received a lot of...Seeking Alpha • Apr 07
Tactile Systems Technology: Interesting Devices Company, Need More Clarity
Summary Tactile Systems produces medical devices for lymphedema and chronic venous insufficiency, with Flexitouch Plus being the flagship product and key revenue driver. The company's products are covered by major insurers, including Medicare and Veterans Administration, serving over 275 million Americans. Financially, TCMD has a market cap of $311mn, but faces risks from increasing competition, regulatory issues, and ongoing legal matters. Despite strong revenue streams, concerns about falling EBITDA and recent revenue misses warrant a cautious approach before making investment decisions. Read the full article on Seeking AlphaArticolo di analisi • Feb 23
Tactile Systems Technology (NASDAQ:TCMD) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Nov 25
Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 26%
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have continued their recent momentum with a 26% gain in the...Articolo di analisi • Nov 07
Tactile Systems Technology, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) came out with its third-quarter results last week, and we wanted to...
Nuova narrativa • Sep 24
Nimbl Approval And Tech Investments Propel Growth Amid Shrinking Margins And Operational Risks
Investments in technology and workflow improvements, alongside FDA approval for Nimbl, indicate a strong focus on innovation and market expansion.Articolo di analisi • Jul 17
Investors Holding Back On Tactile Systems Technology, Inc. (NASDAQ:TCMD)
With a price-to-sales (or "P/S") ratio of 1.1x Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) may be sending very...Articolo di analisi • May 09
US$20.67: That's What Analysts Think Tactile Systems Technology, Inc. (NASDAQ:TCMD) Is Worth After Its Latest Results
Last week, you might have seen that Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) released its quarterly result to...Articolo di analisi • Feb 23
Tactile Systems Technology, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) filed its yearly result this time...Articolo di analisi • Oct 10
Does Tactile Systems Technology (NASDAQ:TCMD) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Sep 16
Capital Allocation Trends At Tactile Systems Technology (NASDAQ:TCMD) Aren't Ideal
What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...Articolo di analisi • Jul 13
Is It Time To Consider Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it saw a significant share...Articolo di analisi • May 10
Are Investors Undervaluing Tactile Systems Technology, Inc. (NASDAQ:TCMD) By 26%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Tactile Systems Technology fair value estimate is US$28.71...Rendimenti per gli azionisti
| TCMD | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | 2.5% | 3.9% | 1.0% |
| 1Y | 191.9% | -14.5% | 19.1% |
Ritorno vs Industria: TCMD ha superato il US Medical Equipment che ha restituito -14.5 % nell'ultimo anno.
Rendimento vs Mercato: TCMD ha superato il mercato US che ha restituito 19.1 % nell'ultimo anno.
Volatilità dei prezzi
| TCMD volatility | |
|---|---|
| TCMD Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: TCMD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di TCMD è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1995 | 1,086 | Sheri Dodd | tactilemedical.com |
Tactile Systems Technology, Inc. è un'azienda di tecnologia medica che sviluppa e fornisce dispositivi medici per il trattamento di malattie croniche poco conosciute negli Stati Uniti. Offre il sistema Flexitouch Plus, un dispositivo di compressione pneumatica per il trattamento di linfedemi, flebolinfedemi, lipedemi, insufficienze venose e altri tipi di edemi e ulcere alle gambe; il sistema Entre Plus, un dispositivo di compressione pneumatica per il trattamento a domicilio di linfedemi, edemi cronici, insufficienze venose e ferite croniche. L'azienda fornisce anche Nimbl, una piattaforma di compressione pneumatica per il trattamento del linfedema dell'arto superiore; Kylee, un'applicazione mobile che aiuta i pazienti a conoscere il linfedema, a tenere traccia dei sintomi e del trattamento, nonché a condividere i propri progressi con il medico; e AffloVest, un gilet portatile ad alta frequenza per l'oscillazione della parete toracica per il trattamento di pazienti con secrezioni polmonari trattenute derivanti da bronchiectasie, fibrosi cistica e vari disturbi neuromuscolari.
Tactile Systems Technology, Inc. Riepilogo dei fondamenti
| TCMD statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$636.09m |
| Utili (TTM) | US$20.30m |
| Ricavi(TTM) | US$343.52m |
31.3x
Rapporto P/E1.8x
Rapporto P/STCMD è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| TCMD Conto economico (TTM) | |
|---|---|
| Ricavi | US$343.52m |
| Costo del fatturato | US$81.11m |
| Profitto lordo | US$262.41m |
| Altre spese | US$242.12m |
| Utili | US$20.30m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 10, 2026
| Utile per azione (EPS) | 0.90 |
| Margine lordo | 76.39% |
| Margine di profitto netto | 5.91% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato TCMD nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/31 20:59 |
| Prezzo dell'azione a fine giornata | 2026/07/31 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Tactile Systems Technology, Inc. è coperta da 12 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | Argus Research Company |
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |